ePrints

The development of antisense oligonucleotide therapies for Duchenne muscular dystrophy: Report on a TREAT-NMD workshop hosted by the European Medicines Agency (EMA), on September 25th 2009

Lookup NU author(s): Emerita Professor Katherine Bushby, Emma HeslopORCiD, Dr Pauline McCormack, Emeritus Professor Simon WoodsORCiD

Downloads

• Accepted version [.pdf]

Licence

This is the authors' accepted manuscript of an article that has been published in its final definitive form by Elsevier, 2010.

For re-use rights please refer to the publisher's terms and conditions.

Publication metadata

Author(s): Muntoni F, Contributors include, Bushby K, Heslop E, McCormack P, Woods S

Publication type: Article

Publication status: Published

Journal: Neuromuscular Disorders

Year: 2010

Volume: 20

Issue: 5

Pages: 355-362

Print publication date: 26/03/2010

Date deposited: 06/06/2013

ISSN (print): 0960-8966

ISSN (electronic): 1873-2364

Publisher: Elsevier

URL: http://dx.doi.org/10.1016/j.nmd.2010.03.005

DOI: 10.1016/j.nmd.2010.03.005

Notes: Report authored by Francesco Muntoni, on behalf of the meeting steering committee, and of the TREAT-NMD Network. Contributors to this document include: Kate Bushby (Institute of Human Genetics, Newcastle University); Emma Heslop (Institute of Human Genetics, Newcastle University); Pauline McCormack (Policy, Ethics and Life Sciences, Newcastle University); and Simon Woods (Policy, Ethics and Life Sciences, Newcastle University).

Altmetrics

Share